GLOBALHealthPR appoints VIVA! Communications ‘Asia-Pacific hub’ & welcomes Spurwing Communications as exclusive Singaporean partner

GLOBALHealthPR, the world’s largest partnership of independent health and science communications agencies, today appointed longstanding Australian partner, VIVA! Communications, ‘regional hub’ for Asia-Pacific. The strategic partnership also welcomed Singapore-based Spurwing Communications to its network today, further strengthening GLOBALHealthPR’s capabilities in the Asia-Pacific (APAC) region. Having earned an enviable reputation for servicing the local, regional and…

The osteoporosis care gap

The release of the Australia and New Zealand Hip Fracture Registry (ANZHFR) 2018 annual reporthas revealed a significant need for improvement in the management and prevention of osteoporotic fractures in our elderly population. There is a call for hospitals to prioritise osteoporosis treatment plans when discharging patients following a hip fracture. This follows data revealing…

New report card on Aussie blokes health + wellness

Findings from a bodyandsoul-commissioned YouGov Galaxy survey released Sunday, September 2, 2018 provide some quirky insights into the current state of Aussie men’s health and wellness. According to the online survey, which captured responses from more than 1,000 men Australia-wide: 68 per cent of respondents had undergone a blood pressure check and 59 per cent…

Fundraising success for the RSPCA as Dogust draws to a close

As GLOBALHealthPR (GHPR) initiative #Dogust draws to conclusion, VIVA! Communications is celebrating the roaring success of our recent fundraising bake sale for the RSPCA. Generating more than $170 through in-person donations alone, VIVA! raised the dough this year by 34 per cent in comparison to the same event last year. Celebrating ‘Cupcake Day’, an annual…

Every drop counts – World Water Week 2018

This week is the World Water Week (WWW) Forum 2018 and this year’s focus is on ‘Water, ecosystems and human development’. Every year, WWW provides a platform for over 300 organisations to consider the latest research and encourage new thinking and positive action towards water-related issues worldwide.  Around 1.1 billion people around the world do not…

Doctors sound alarm bell at lack of qualified nurses in aged care sector

Doctors have this week raised an alarm regarding the lack of qualified nurses working in the Australian aged care sector. According to the AMA’s most recent Aged Care survey, 35% of doctor respondents plan to stop accepting new patients, to reduce or completely cease their aged-care visits within the next two years. The survey involved…

Pharmaxis granted FDA clearance to produce Aridol locally for US market

ASX-listed pharmaceutical company, Pharmaxis has today been granted FDA clearance to commence Sydney-based production of its asthma diagnostic medication, Aridol for the US. The approval follows hot-on-the-heels of the FDA’s recent inspection of the Sydney facility which manufactures Aridol for Australia, South Korea and Europe, and Bronchitol for Australia, Europe and Russia respectively. Following FDA…

Doctors encouraging middle-aged Aussie blokes to consider their prostate

Doctors are encouraging middle-aged Aussie blokes to have their prostate checked.Their call coincides with an article published in MJA Insight today (Monday, August 13), citing benign prostatic hyperplasia (BPH) – or a benign enlargement of the prostate –  can compromise a man’s quality of life, and his relationships with his partner and family.2   According…

Seqirus to release additional 700,000 adult flu vaccine doses to help boost “community immunity” against preventable infection

Seqirus announced the manufacture of another 500,000 doses of their adult influenza vaccine, Afluria Quad (inactivated quadrivalent influenza vaccine, split virion) today to help meet increasing consumer demand. Having fulfilled the government’s request to re-enter production, Seqirus is now ahead of the National Immunisation Program (NIP) schedule, with its first vaccine set for release this…

Mundipharma pioneering prostate cancer research in Australia

A Medical Oncologist from Chris O’Brien Lifehouse, Sydney has recently clinched a $60,000 2018 Mundipharma ANZUP Uro-Oncology Clinical Research Fellowship to support her research into prostate cancer. Dr Kate Mahon is the fifth recipient of the annual Clinical Research Fellowship awarded in partnership with the Australian and New Zealand Urogenital and Prostate Cancer Trials Group…